Catalyst Pharmaceuticals Announces FDA Approval To Increase Maximum Daily Dose Of FIRDAPSE For LEMS Treatment From 80 mg To 100 mg
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharmaceuticals has received FDA approval to increase the maximum daily dose of FIRDAPSE for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) from 80 mg to 100 mg.
May 30, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalyst Pharmaceuticals has received FDA approval to increase the maximum daily dose of FIRDAPSE for LEMS treatment from 80 mg to 100 mg. This approval could potentially lead to increased sales and revenue for the company.
The FDA approval to increase the maximum daily dose of FIRDAPSE is likely to positively impact Catalyst Pharmaceuticals by potentially increasing the drug's usage and sales. This regulatory milestone can enhance the company's revenue and market position in the treatment of LEMS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100